FIA
REGN icon

FNY Investment Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

FNY Investment Advisers’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-31
Closed -$22K – 937
2024
Q4 		$22K Buy
+31
New +$26K 0.01% 419

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Amundi
Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

FNY Investment Advisers's REGN Position: Q2 2026 in Review

FNY Investment Advisers held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 50 shares worth $31K. The position accounts for 0.01% of the portfolio, ranked #480.

FNY Investment Advisers first reported a position in REGN in Q3 2018 and has held it in 6 quarters since. The position peaked at $78K in Q2 2025. 955 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • FNY Investment Advisers held 50 shares of Regeneron Pharmaceuticals worth $31K as of Q2 2026.
  • FNY Investment Advisers left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.01% of FNY Investment Advisers's portfolio in Q2 2026, its #480 holding.
  • FNY Investment Advisers first reported a position in Regeneron Pharmaceuticals in Q3 2018 and has held it in 6 quarters since.
  • FNY Investment Advisers's Regeneron Pharmaceuticals position peaked at $78K in Q2 2025.
  • 955 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.